Weiyi Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Weiyi Tan has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
Jamil Aboulhosn
Division of Cardiology, Department of Medicine, University of California Los Angeles, Adult Congenital Heart Disease, Los Angeles, California
8 shared publications- Jamil Aboulhosn
University of California, Los Angeles
8 shared publications - Katia Bravo-Jaimes
Department of Cardiovascular Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA
3 shared publications - Ahmed Zaghloul
Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
2 shared publications - Amit Goyal
Department of Internal Medicine, Division of Cardiovascular Medicine, UT Southwestern Medical Center, Dallas, TX (J.K., M.A.R., A.P., S.G., M.B., A.G., G.P., G.A., J.A.D., A.S., D.J.K.).
2 shared publications - Anthony A. Bavry
University of Texas Southwestern Medical Center
2 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3405
A Contemporary Approach to the Management of Asymptomatic Severe Aortic Stenosis
Asymptomatic severe aortic stenosis (AS) is characterized by a prolonged latent phase during which progressive valvular obstruction and myocardial remodeling may occur despite preserved left ventricular ejection fraction and the absence of overt clinical symptoms. Historically, management has favored watchful waiting until symptom onset or guideline-defined triggers emerge; however, recent randomized data challenge this conservative paradigm. This review summarizes the natural history, risk stratification, and contemporary management of asymptomatic severe AS, with a focus on emerging insights that inform the timing of intervention. We propose an individualized, contemporary framework for managing asymptomatic severe AS that integrates multimodal risk assessment, procedural risk, and shared decision-making, and we outline future directions aimed at refining patient selection and optimizing the personalized timing of intervention.
- 29 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3405
Open AccessA Contemporary Approach to the Management of Asymptomatic Severe Aortic Stenosis
Asymptomatic severe aortic stenosis (AS) is characterized by a prolonged latent phase during which progressive valvular obstruction and myocardial remodeling may occur despite preserved left ventricular ejection fraction and the absence of overt clinical symptoms. Historically, management has favored watchful waiting until symptom onset or guideline-defined triggers emerge; however, recent randomized data challenge this conservative paradigm. This review summarizes the natural history, risk stratification, and contemporary management of asymptomatic severe AS, with a focus on emerging insights that inform the timing of intervention. We propose an individualized, contemporary framework for managing asymptomatic severe AS that integrates multimodal risk assessment, procedural risk, and shared decision-making, and we outline future directions aimed at refining patient selection and optimizing the personalized timing of intervention.
- 13 January 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (2) , 82-85
When Less Is More: Is It Time for a New Gold Standard?
- 13 January 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (2) , 82-85
When Less Is More: Is It Time for a New Gold Standard?
- 15 May 2025
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 38 (4) , 497-498
Fontan and pregnancy: walking a tightrope
- 15 May 2025
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 38 (4) , 497-498
Fontan and pregnancy: walking a tightrope
- Open Access
- 18 March 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (11) , 744-756
Covered Stent Correction for Sinus Venosus Atrial Septal Defects, an Emerging Alternative to Surgical Repair: Results of an International Registry
BACKGROUND: Covered stent correction for a sinus venosus atrial septal defect (SVASD) was first performed in 2009. This innovative approach was initially viewed as experimental and was reserved for highly selected patients with unusual anatomic variants. In 2016, increasing numbers of procedures began to be performed, and in several centers, it is now offered as a standard of care option alongside surgical repair. However, covered stent correction for SVASD is not recognized by regulatory authorities, and in the minds of many pediatric and adult congenital cardiologists and surgeons, the condition is viewed as treatable only by cardiac surgery with cardiopulmonary bypass. METHODS: In April 2023, all centers identified from international conferences, publications, and colleague networks to be undertaking covered stent correction for SVASD were invited to participate in a retrospective audit of their procedures. RESULTS: Data were received on 381 patients from 54 units over a 12-year period with 90% of procedures being performed over the past 5 years. Balloon-expandable stents (8 types) were used in the majority; self-expanding stents (4 types) were used in 4.5%. The commonest stent was the 10-zig covered Cheatham Platinum stent in 62% of cases. In 10 procedures, the stent embolized requiring surgical retrieval and repair of the defect, resulting in technically successful implantation in 371 of 381 (97.4%). Major complications (surgical drainage of tamponade, pacemaker implantation, surgery for pulmonary vein occlusion, and late stent removal) occurred in 5 patients (1.3%). Repeat catheterization to correct residual leaks was required in 7 patients (1.8%). Thus, 359 of 381 patients (94.2%) had successful correction without major complications or additional catheter interventions. CONCLUSIONS: This article details the exponential uptake of covered stent correction for SVASD during the past 5 years. Cardiopulmonary bypass was avoided in the majority of patients, and major complications were infrequent. Prospective registries with standardized definitions, inclusion criteria, and follow-up and comparative studies with surgery are now required to help support the extension of covered stent correction as an alternative standard-of-care option for patients with an SVASD.
- 18 March 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (11) , 744-756
Open AccessCovered Stent Correction for Sinus Venosus Atrial Septal Defects, an Emerging Alternative to Surgical Repair: Results of an International Registry
BACKGROUND: Covered stent correction for a sinus venosus atrial septal defect (SVASD) was first performed in 2009. This innovative approach was initially viewed as experimental and was reserved for highly selected patients with unusual anatomic variants. In 2016, increasing numbers of procedures began to be performed, and in several centers, it is now offered as a standard of care option alongside surgical repair. However, covered stent correction for SVASD is not recognized by regulatory authorities, and in the minds of many pediatric and adult congenital cardiologists and surgeons, the condition is viewed as treatable only by cardiac surgery with cardiopulmonary bypass. METHODS: In April 2023, all centers identified from international conferences, publications, and colleague networks to be undertaking covered stent correction for SVASD were invited to participate in a retrospective audit of their procedures. RESULTS: Data were received on 381 patients from 54 units over a 12-year period with 90% of procedures being performed over the past 5 years. Balloon-expandable stents (8 types) were used in the majority; self-expanding stents (4 types) were used in 4.5%. The commonest stent was the 10-zig covered Cheatham Platinum stent in 62% of cases. In 10 procedures, the stent embolized requiring surgical retrieval and repair of the defect, resulting in technically successful implantation in 371 of 381 (97.4%). Major complications (surgical drainage of tamponade, pacemaker implantation, surgery for pulmonary vein occlusion, and late stent removal) occurred in 5 patients (1.3%). Repeat catheterization to correct residual leaks was required in 7 patients (1.8%). Thus, 359 of 381 patients (94.2%) had successful correction without major complications or additional catheter interventions. CONCLUSIONS: This article details the exponential uptake of covered stent correction for SVASD during the past 5 years. Cardiopulmonary bypass was avoided in the majority of patients, and major complications were infrequent. Prospective registries with standardized definitions, inclusion criteria, and follow-up and comparative studies with surgery are now required to help support the extension of covered stent correction as an alternative standard-of-care option for patients with an SVASD.
- Open Access
- 28 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1651
Access Options for Transcatheter Aortic Valve Replacement
Transcatheter aortic valve replacement (TAVR) was introduced in 2002 and has become integral in the management of aortic stenosis. As an alternative to surgical aortic valve replacement, it relies heavily on safe access to the aortic annulus for implantation of a valve prosthesis. Throughout its development and in current practice, the transfemoral (TF) arterial route for retrograde valve delivery has been the primary approach. However, this route is not appropriate for all patients, which has led to the development of multiple alternate access options. This review discusses the development of access for TAVR, followed by a thorough discussion of TF access. The commercially available products, preprocedural planning, closure techniques, and procedural complications are all discussed. We also describe the various alternate access routes with particular emphasis on the most recently developed route, transcaval access (TCv), with focus on procedural indications, technical considerations, and comparative outcomes. As TAVR technology, indications, and availability all expand, the knowledge and implementation of safe access are of utmost importance.
- 28 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1651
Open AccessAccess Options for Transcatheter Aortic Valve Replacement
Transcatheter aortic valve replacement (TAVR) was introduced in 2002 and has become integral in the management of aortic stenosis. As an alternative to surgical aortic valve replacement, it relies heavily on safe access to the aortic annulus for implantation of a valve prosthesis. Throughout its development and in current practice, the transfemoral (TF) arterial route for retrograde valve delivery has been the primary approach. However, this route is not appropriate for all patients, which has led to the development of multiple alternate access options. This review discusses the development of access for TAVR, followed by a thorough discussion of TF access. The commercially available products, preprocedural planning, closure techniques, and procedural complications are all discussed. We also describe the various alternate access routes with particular emphasis on the most recently developed route, transcaval access (TCv), with focus on procedural indications, technical considerations, and comparative outcomes. As TAVR technology, indications, and availability all expand, the knowledge and implementation of safe access are of utmost importance.
- 12 March 2023
- Published by Springer Nature
- p. 729-758
Transcatheter Interventional Techniques in the Adult Congenital Heart Disease Patient
- 12 March 2023
- Published by Springer Nature
- p. 729-758
Transcatheter Interventional Techniques in the Adult Congenital Heart Disease Patient
- 1 January 2023
- Published by Springer Nature
- p. 327-336
Catheter-Based Interventions in Adult Life for the Failing Adult Fontan Patient
- 1 January 2023
- Published by Springer Nature
- p. 327-336
Catheter-Based Interventions in Adult Life for the Failing Adult Fontan Patient